K Park1, S Han, E Shin, H-J Kim, J-Y Kim. 1. Department of Pathology, Inje University, Sanggye Paik Hospital, 761-1, Sanggye-dong, Nowon-gu, Seoul 139-707, South Korea.
Abstract
AIM: To measure cyclooxygenase-2 (Cox-2) expression in a series of breast cancers and evaluate its potential as a predictive marker for doxorubicin chemotherapy. PATIENTS AND METHODS: Cox-2 expression was analyzed in 178 node-positive patients treated with doxorubicin-based adjuvant chemotherapy by immunohistochemistry on tissue microarray (TMA). RESULTS: Cox-2 was over-expressed in 70 out of the 178 invasive breast cancers. Cox-2 expression was significantly increased in undifferentiated tumors. There was no significant association between Cox-2 over-expression and tumor size, histologic grade, and estrogen receptor expression. Disease-free survival and overall survival of the patients having Cox-2 expressing tumor were significantly decreased when compared with the patients having Cox-2 negative tumor (p=0.009 for DFS, p=0.011 for OS). CONCLUSION: Cox-2 expression may represent an aggressive phenotype of breast cancer which is resistant to doxorubicin.
AIM: To measure cyclooxygenase-2 (Cox-2) expression in a series of breast cancers and evaluate its potential as a predictive marker for doxorubicin chemotherapy. PATIENTS AND METHODS: Cox-2 expression was analyzed in 178 node-positive patients treated with doxorubicin-based adjuvant chemotherapy by immunohistochemistry on tissue microarray (TMA). RESULTS:Cox-2 was over-expressed in 70 out of the 178 invasive breast cancers. Cox-2 expression was significantly increased in undifferentiated tumors. There was no significant association between Cox-2 over-expression and tumor size, histologic grade, and estrogen receptor expression. Disease-free survival and overall survival of the patients having Cox-2 expressing tumor were significantly decreased when compared with the patients having Cox-2 negative tumor (p=0.009 for DFS, p=0.011 for OS). CONCLUSION:Cox-2 expression may represent an aggressive phenotype of breast cancer which is resistant to doxorubicin.
Authors: Michelle D Holmes; Wendy Y Chen; Stuart J Schnitt; Laura Collins; Graham A Colditz; Susan E Hankinson; Rulla M Tamimi Journal: Breast Cancer Res Treat Date: 2011-07-05 Impact factor: 4.872
Authors: Karla Esbona; Yanyao Yi; Sandeep Saha; Menggang Yu; Rachel R Van Doorn; Matthew W Conklin; Douglas S Graham; Kari B Wisinski; Suzanne M Ponik; Kevin W Eliceiri; Lee G Wilke; Patricia J Keely Journal: Am J Pathol Date: 2018-03 Impact factor: 4.307
Authors: Mohammad A Mohammad; Ahmed A Zeeneldin; Zakaria Y Abd Elmageed; Ebtsam H Khalil; Said M E Mahdy; Hayat M Sharada; Sabry K Sharawy; Abdel-Hady A Abdel-Wahab Journal: Mol Cell Biochem Date: 2012-04-18 Impact factor: 3.396
Authors: Sharon A Glynn; Robyn L Prueitt; Lisa A Ridnour; Brenda J Boersma; Tiffany M Dorsey; David A Wink; Julie E Goodman; Harris G Yfantis; Dong H Lee; Stefan Ambs Journal: BMC Cancer Date: 2010-11-15 Impact factor: 4.430